#United States #San Diego #Monoclonal Antibodies #IgGenix #Alpha-gal Syndrome

IgGenix's Promising Discovery on Alpha-gal Syndrome

IgGenix, Inc., a forward-thinking biotechnology company focusing on immune-mediated conditions, is set to present new research at the upcoming 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress, taking place from February 28 to March 3, 2025, in sunny San Diego, California. This presentation will focus on their groundbreaking discoveries regarding alpha-gal-specific monoclonal antibodies (mAbs) which are derived from individuals suffering from red meat allergies.

Understanding Alpha-gal Syndrome

Alpha-gal Syndrome (AGS) is a complex condition that can significantly alter the daily lives of those impacted. Characterized by an allergic reaction triggered by consuming red meat, AGS is often poorly understood, making it crucial for researchers to unravel its intricacies. According to Dr. Jessica Grossman, CEO of IgGenix, understanding the mechanisms behind AGS is vital for addressing its challenging effects on patients. This breakthrough lays down a vital piece of knowledge that could lead to novel treatments for AGS and similar conditions.

The Discovery Process

Isolating the mAbs responsible for AGS in humans is a challenging endeavor due to the rarity of specific B cells that produce these antibodies. Using their proprietary SEQ SIFTER™ technology, IgGenix was able to identify over 60 different monoclonal antibodies sourced from several red meat-allergic individuals. Notably, the antibodies demonstrated a specific binding affinity range, which, despite diverging variable domain gene usage and antibody maturation, indicates the unique molecular mechanisms that delineate AGS from conventional food protein allergies. Clonal families of related antibodies exhibited longevity over time, proposing a basis for immunological memory related to AGS.

Presentation Highlights

The abstract titled "Alpha-gal Specific Monoclonal Antibodies Discovered from Red Meat Allergic Individuals" will feature prominently in the conference's poster session. Here are the key details of the presentation:

• - Poster Number: 843
• - Session Title: Novel Genes and Biomarkers of Allergic Disease
• - Session Type: Poster Session
• - Session Date/Time: Sunday, March 2, 9:45 am - 10:45 am

About IgGenix

IgGenix is committed to revolutionizing allergy treatment and management through the discovery of targeted antibodies. Founded by experts including Stephen Quake, Kari Nadeau, and Derek Croote from Stanford University, the SEQ SIFTER™ platform is designed to isolate and engineer human, allergen-specific antibodies designed to disrupt the allergic response. The goal of IgGenix is to protect patients from the life-threatening implications of allergies across various conditions, including both food and environmental allergies. Their innovative approach has the potential to transform the treatment landscape for millions affected by allergies, ultimately reducing the chronic anxiety linked to severe allergic reactions.

In conclusion, IgGenix is poised to significantly contribute to the medical understanding and treatment of Alpha-gal Syndrome at the upcoming congress, offering hope for better therapeutic options in the future.